The GUSTO trial in the UK aims to tailor treatments for muscle-invasive bladder cancer (MIBC) based on genetic subtypes. Led by Jim Catto, the study involves collaboration among various healthcare teams, including pathologists and oncologists, to provide rapid gene expression results within seven days. This phase 2 trial enhances understanding of individualized care pathways and aims to inform future definitive trials. The innovative lab processes have earned recognition from the Royal College of Pathologists, underscoring the importance of academic and clinical partnerships in advancing cancer diagnostics.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.